首页 | 本学科首页   官方微博 | 高级检索  
     


Design,synthesis, and biological evaluation of pyrimidine derivatives as potential inhibitors of human calcium/calmodulin‐dependent protein kinase IV
Authors:Parvez Khan  Mohd. Tarique  Jitendra Kumar  Syed Mumtazuddin  Shahzaib Ahamad  Asimul Islam  Faizan Ahmad  Nasimul Hoda  Md. Imtaiyaz Hassan
Affiliation:1. Centre for Interdisciplinary Research in Basic Sciences, Jamia Millia Islamia, New Delhi, India;2. Department of Biochemistry, All India Institute of Medical Sciences, New Delhi, India;3. Department of Chemistry, Jamia Millia Islamia, New Delhi, India;4. Department of Chemistry, B.R. Ambedkar Bihar University, Muzaffarpur, Bihar, India;5. Department of Biotechnology, College of Engineering and Technology, IFTM, Moradabad, India
Abstract:Calcium/calmodulin‐dependent protein kinase IV (CAMKIV ) is a multifunctional Ser/Thr kinase, associated with cerebral hypoxia, cancer, and neurodegenerative diseases. Here, we report design, synthesis, and biological evaluation of seven pyrimidine‐substituted novel inhibitors of CAMKIV . We successfully synthesized and extensively characterized (ESI ‐MS , 1H NMR , and 13C NMR studies) seven compounds that are showing appreciable binding affinity to the CAMKIV . Molecular docking and fluorescence binding studies revealed that compound 1 is showing very high binding free energy (Δ= ?11.52 kcal/mol) and binding affinity (=  9.2 × 1010 m ?1) to the CAMKIV . We further performed MTT assay to check the cytotoxicity and anticancer activity of these compounds. An appreciable IC 50 (39 μm ) value of compound 1 was observed on human hepatoma cell line and nontoxic till the 400 μm on human embryonic kidney cells. To ensure anticancer activity of all these compounds, we further performed propidium iodide assay to evaluate cell viability and DNA content during the cell cycle. We found that compound 1 is again showing a better anticancer activity on both human hepatoma and human embryonic kidney cell lines.
Keywords:anticancer activity  calcium/calmodulin‐dependent protein kinase IV  drug design and discovery  high‐affinity ligands  molecular docking
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号